Beta-Thalassemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Beta-thalassemia (BT) is a genetic disorder characterized by a deficiency (Beta+) or absence (Beta0) of the beta-globin chains of hemoglobin (Hb). There are three main types of BT: BT-minor, BT-major, and BT-intermedia. BT-minor is the heterozygous form and is generally asymptomatic. At the same time, BT-major is the homozygous form that causes splenomegaly, microcytic and hypochromic anemia, and requires systematic transfusions to maintain Hb levels above 90-100 g/L. Long-term transfusion results in iron overload, which can cause significant morbidity and hamper the vital prognosis. BT-intermedia is less severe than BT-major and diagnosed later in life, and patients may or may not require occasional transfusions. Diagnosis of BT relies on analyzing Hb by electrophoresis or HPLC. Treatment options for BT include a combination of regular transfusions and iron chelation therapy, which has led to increased survival during the last 40 years. The prognosis depends on the severity of the condition, mainly if appropriate treatment is provided.
·
In the United States, β‐thalassemia, the
reported incidence is 1 in 55,000 newborns.
Thelansis’s “Beta-Thalassemia Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Beta-Thalassemia treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Beta-Thalassemia across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Beta-Thalassemia Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment